Aviceda Raises $207.5M for AVD-104 Phase 3 Trial | OBN

Aviceda Raises $207.5M For AVD-104 Phase 3 Trial | OBN

3 weeks from now

Jan 9, 2025  · Aviceda Therapeutics Secures $207.5 Million to Advance AVD-104 for Geographic Atrophy January 09, 2025 Aviceda Therapeutics has successfully closed a $207.5 million …

ophthalmologybreakingnews.com

Aviceda Therapeutics Raises $207.5 Million To Advance Lead …

3 weeks from now

Jan 8, 2025  · Aviceda Therapeutics announced the closing of a $207.5 million Series C financing to propel the company’s pivotal phase 3 clinical trial for AVD-104, a treatment candidate for …

eyewire.news

Aviceda Raises $207.5m For Eye Drug, And Other Financings

3 weeks from now

Jan 30, 2025  · Aviceda Therapeutics has got biotech financing in 2025 off to a flying start by raising $207.5 million to take its lead drug for sight-robbing disease geographic atrophy (GA) …

pharmaphorum.com

Aviceda Therapeutics Raises Upsized $207.5 Million In Series C ...

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials Business Wire …

yahoo.com

Aviceda Therapeutics Raises Upsized $207.5 Million In Series C ...

3 weeks from now

Jan 7, 2025  · This raise reflects the strong conviction from investors in Aviceda’s lead program AVD-104 for geographic atrophy—a market poised for disruption and an improved standard of …

businesswire.com

Aviceda Raises $207M For Geographic Atrophy Drug's Ph. 3 Journey

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this year for its lead eye disease …

fiercebiotech.com

Aviceda Raises $207.5 Million In Series C Funding To Advance

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics secured $207.5 million in Series C financing to advance the AVD-104 program in geographic atrophy, according to a press release.. Omega Funds and …

healio.com

Aviceda Therapeutics Raises Upsized $207.5 Million In Series C ...

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials. January 7, …

biospace.com

Aviceda Therapeutics Completes $207.5 Million Series C Financing …

3 weeks from now

Jan 9, 2025  · The company also announced that in connection with the Series C financing, Bernard Davitian of Omega Funds and Chen Yu, MD, MBA, of TCGX have joined Aviceda’s …

ophthalmologytimes.com

Aviceda Therapeutics Raises Upsized $207.5 Million In Series C ...

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials. Recent Quotes …

financialcontent.com

Aviceda Therapeutics: $207.5 Million (Series C) Raised To Develop …

3 weeks from now

Jan 8, 2025  · Aviceda Therapeutics, a private, clinical-stage biotech company focused on developing next-generation immunomodulators with a proprietary High Affinity Ligands of …

pulse2.com

Jeito Capital Announces Significant Participation In Upsized $207.5 ...

3 weeks from now

Jan 7, 2025  · Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy …

yahoo.com

Aviceda Therapeutics Raises Upsized $207.5M In Series C Financing

3 weeks from now

Jan 8, 2025  · Aviceda Therapeutics, a Cambridge, MA-based private, clinical-stage biotech company focused on developing new immunomodulators, raised $207.5M in Series C …

finsmes.com

Aviceda Raises $207M Series C To Take Geographic Atrophy Drug …

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics has secured $207.5 million in series C funds as the immunomodulator-focused biotech awaits a phase 3 readout this year for its lead eye disease …

biotechnetworks.org

Jeito Capital Announces Significant Participation In Upsized $207.5 ...

3 weeks from now

Jan 7, 2025  · Morningstar brands and products Company Portfolio

morningstar.com

Aviceda Therapeutics Raises Upsized $207.5 Million In Series C ...

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials ... This raise …

enavatesciences.com

Jeito Capital Announces Significant Participation In Upsized $207.5 ...

3 weeks from now

Jan 7, 2025  · Jeito Capital announces significant participation in upsized $207.5 million Series C financing in Aviceda Therapeutics to advance Lead Program AVD-104 for Geographic Atrophy …

kauppalehti.fi

Aviceda Therapeutics Raises Upsized $207.5 Million In Series C

3 weeks from now

Jan 7, 2025  · Aviceda Therapeutics Raises Upsized $207.5 Million in Series C Financing Round to Advance Lead Program AVD-104 for Geographic Atrophy into Pivotal Trials ... Explore …

advfn.com

Series C - Aviceda Therapeutics - 2025-01-07 - Crunchbase

3 weeks from now

Jan 8, 2025  · Aviceda Therapeutics raised $207500000 on 2025-01-07 in Series C. Start Free Trial . Chrome Extension

crunchbase.com

Jeito Capital Announces Significant Participation In Upsized $207.5 ...

3 weeks from now

Paris, France, January 7 th, 2025 – Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, announced today its significant participation in the …

financialcontent.com